Advertisement

Effects of pregabalin on spinal fusion

  • Erdi İmre
  • Mert ÇiftdemirEmail author
  • Ebru Taştekin
Original Article

Abstract

Purpose

Gamma-aminobutyric acid analogues are commonly used to treat neuropathic and chronic pain before and after spinal surgery in recent years. Aim of this study is to investigate the influence of pregabalin on spinal fusion and to determine the proper pregabalin dose for postoperative utilization in a validated rat intertransverse spinal fusion.

Methods

Lumbar intertransverse fusion surgeries performed in four groups of rats according to a previously established rat model for posterolateral spinal fusion. All rats were followed up for 6 weeks at the postoperative period by administering oral pregabalin doses of 10 (D10), 30 (D30) and 100 mg/kg/day (D100) except the control group. All rats were killed after 6 weeks and evaluated in terms of manual palpation, radiographic investigation and histological analysis to investigate posterolateral fusion.

Results

Assessment of fusion with manual palpation revealed lower fusion rates in D100 group. In histological analysis, scores were significantly lower in D30 and D100 groups compared to the control group; this finding was interpreted as inhibition of spinal fusion. Radiographic evaluation did not reveal any significant statistical difference between groups.

Conclusions

Histological analysis and manual palpation results showed inhibition of spinal fusion formation with high doses of pregabalin. According to these results, administration of high-dose pregabalin should be avoided at the postoperative period until successful fusion is obtained in patients who undergo spinal fusion surgery.

Graphic abstract

These slides can be retrieved under electronic supplementary material.

Keywords

Spinal fusion Pregabalin Neuropathic pain Bone healing 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

Supplementary material

586_2019_6226_MOESM1_ESM.pptx (138 kb)
Supplementary material 1 (PPTX 138 kb)

References

  1. 1.
    Gajraj NM (2007) Pregabalin: its pharmacology and use in pain management. Anesth Analg 105(6):1805–1815CrossRefGoogle Scholar
  2. 2.
    Enke O, New HA, New CH, Mathieson S, McLachlan AJ, Latrimer J, Maher CG, Lin CC (2018) Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis. CMAJ 190(26):E786–E793CrossRefGoogle Scholar
  3. 3.
    Mathieson S, Valenti L, Maher CG, Britt H, Li Q, McLachlan AJ, Lin CC (2018) Worsening trends in analgesics recommended for spinal pain in primary care. Eur Spine J 27(5):1136–1145CrossRefGoogle Scholar
  4. 4.
    Bydon M, De la Garza-Ramos R, Macki M, Baker A, Gokaslan AK, Bydon A (2014) Lumbar fusion versus nonoperative management for treatment of discogenic low back pain: a systematic review and meta-analysis of randomized controlled trials. J Spinal Disorders Tech 27(5):297–304CrossRefGoogle Scholar
  5. 5.
    Turan A, Karamanlioglu B, Memis D, Hamamcioglu MK, Tukenmez B, Pamukcu Z, Kurt I (2004) Analgesic effects of gabapentin after spinal surgery. Anesthesiology 100(4):935–938CrossRefGoogle Scholar
  6. 6.
    Siemienow KB, Muschler GF (2011) Principles of bone fusion. In: Herkowitz HN, Garfin SR, Eismont FJ, Bell GR, Balderston RA (eds) The spine, 6th edn. Saunders, Philadelphia, pp 1130–1158Google Scholar
  7. 7.
    Perinpanayagam J, Abu-Asi MJ, Bustamante S, Kunnumpurath S (2015) Opioid-sparing drugs (ketamine, gabapentin, pregabalin, and clonidine). In: Kaye AD, Vadivelu N, Urman RD (eds) Substance abuse, 1st edn. Springer, Heidelberg, pp 319–330CrossRefGoogle Scholar
  8. 8.
    European Medicines Agency (EMEA) (2005) Initial marketing-authorization documents. https://www.ema.europa.eu/en/medicines/human/EPAR/lyrica. Accessed 25 July 2019
  9. 9.
    Gezici AR, Ergun R, Gurel K, Yilmaz F, Okay O, Bozdogan O (2009) The effect of risedronate on posterior lateral spinal fusion in a rat model. J Korean Neurosurg Soc 46(1):45–51CrossRefGoogle Scholar
  10. 10.
    Grauer JN, Patel TC, Erulkar JS, Troiano NW, Panjabi MM, Friedlander GE (2001) Evaluation of OP-1 as a graft substitute for intertransverse process lumbar fusion. Spine 26(2):127–133CrossRefGoogle Scholar
  11. 11.
    Boden SD, Schimandle JH, Hutton WC (1995) An experimental lumbar intertransverse process spinal fusion model. Radiographic, histologic, and biomechanical healing characteristics. Spine 20(4):412–420CrossRefGoogle Scholar
  12. 12.
    Schimandle JH, Boden SH, Hutton WC (1995) Experimental spinal fusion with recombinant human bone morphogenetic protein-2. Spine 20(12):1326–1337CrossRefGoogle Scholar
  13. 13.
    Kiter E, Er E, Sen Turk N, Oto M, Akkaya S (2014) Efficacy of 5-Fluorouracil in inhibition of unintended bone formation in spinal surgery: a histological evaluation on a rat model of spontaneous spinal fusion. Acta Orthop Traumatol Turc 48(1):86–91PubMedGoogle Scholar
  14. 14.
    Emery SE, Brazinski MS, Koka A, Bensusan JS, Stevenson S (1994) The biological and biomechanical effects of irradiation on anterior spinal bone grafts in a canine model. J Bone Joint Surg Am 76(4):540–548CrossRefGoogle Scholar
  15. 15.
    He Y, Revel M, Loty B (1995) A quantitative model of post-laminectomy scar formation. Effects of a nonsteroidal anti-inflammatory drug. Spine 20(5):557–563CrossRefGoogle Scholar
  16. 16.
    Kanda J, Izumo N, Kobayashi Y, Onodera K, Shimakura T, Yamamoto N, Takahashi HE, Wakabayashi H (2017) Effects of the antiepileptic drugs phenytoin, gabapentin, and levetiracetam on bone strength, bone mass, and bone turnover in rats. Biol Pharm Bull 40(11):1934–1940CrossRefGoogle Scholar
  17. 17.
    Yamaguchi K, Kumakura S, Someya A, Iseki M, Inada E, Nagaoka I (2017) Anti-inflammatory actions of gabapentin and pregabalin on the substance P-induced mitogen-activated protein kinase activation in U373 MG human glioblastoma astrocytoma cells. Mol Med Rep 16(5):6109–6115CrossRefGoogle Scholar
  18. 18.
    Ishida W, Elder BD, Holmes C, Lo SL, Witham TF (2016) Variables affecting fusion rates in the rat posterolateral spinal fusion model with autogenic/allogenic bone grafts: a meta-analysis. Ann Biomed Eng 44(11):3186–3201CrossRefGoogle Scholar
  19. 19.
    Hahm TS, Ahn HJ, Ryu S, Gwak MS, Choi SJ, Kim JK, Yu JM (2012) Combined carbamazepine and pregabalin therapy in a rat model of neuropathic pain. Br J Anaesth 109(6):968–974CrossRefGoogle Scholar
  20. 20.
    Sandhu HS, Khan SN, Suh DY, Boden SD (2001) Demineralized bone matrix, bone morphogenetic proteins, and animal models of spine fusion: an overview. Eur Spine J 10(Suppl 2):S122–S131PubMedPubMedCentralGoogle Scholar
  21. 21.
    Kockara N, Sofu H, Issın A, Cetinkaya M (2017) Pregabalin does not affect fracture healing adversely. Eklem Hastalik Cerrahisi 28(1):19–24CrossRefGoogle Scholar
  22. 22.
    Carano RA, Filvaroff EH (2003) Angiogenesis and bone repair. Drug Discovery Today 8(21):980–989CrossRefGoogle Scholar
  23. 23.
    Verma V, Singh N, Singh Jaggi A (2014) Pregabalin in neuropathic pain: evidences and possible mechanisms. Curr Neuropharmacol 12(1):44–56CrossRefGoogle Scholar
  24. 24.
    Fehrenbacher JC, Taylor CP, Vasko MR (2003) Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 105(1–2):133–141CrossRefGoogle Scholar
  25. 25.
    Ha Y, Carragee E, Cheng I, Kwon SE, Kim YH (2011) Pregabalin as a neuroprotector after spinal cord injury in rats: biochemical analysis and effect on glial cells. J Korean Med Sci 26(3):404–411CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Afşin State HospitalKahramanmaraşTurkey
  2. 2.Department of Orthopedics and Traumatology, Faculty of MedicineTrakya UniversityEdirneTurkey
  3. 3.Department of Pathology, Faculty of MedicineTrakya UniversityEdirneTurkey

Personalised recommendations